Glioblastoma (GBM) represents the most aggressive primary malignant tumor of the adult central nervous system, with an extremely poor clinical prognosis. As the first-line chemotherapeutic agent for GBM, temozolomide (TMZ) has encountered a critical therapeutic bottleneck due to the development of drug resistance in tu...
Ying Qin, Yu-Fang Zhao, Bo-Wen Li et al.· Biochimica et biophysica act...· 0 citations
BACKGROUND
Recurrent IDH-mutant gliomas frequently acquire increased radioresistance, leading to poorer outcomes. Their underlying mechanisms, however, remain largely unknown. We hypothesize that dysregulated RNA alternative splicing (AS) during IDH-mutant glioma recurrence contributes to the enhanced radioresistance b...
A heterogeneity-informed framework for patient stratification and precision immunotherapy development in GBM is proposed, and major translational challenges are highlighted, including blood-brain barrier penetration, cell-type-specific pathway activation, treatment-induced pathway remodeling, and biomarker selection.
Yu-Zhu Long, Tong-Cui Jiang, Yu Long et al.· Biomedicine & pharmacotherap...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
